Has Srilata Gundala, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,276,835 in general payments to Srilata Gundala, MD across 690 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Srilata Gundala, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Srilata Gundala, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Srilata Gundala, MD

Hematology & Oncology · Hinsdale, ILNPI 1467646141

Payments from drug & device makers

$3,276,835in general payments, 2019–2025

Across 690 payments — averaging $4749.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Aadi Bioscience, Inc.$690K
Novartis$598K
Pfizer$347K
Regeneron$298K
AstraZeneca$225K
AbbVie$219K
plus $900K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Aadi Bioscience, Inc.	28	$689,619
Novartis	51	$598,253
Pfizer	51	$347,055
Regeneron	66	$297,784
AstraZeneca(2 entities)	39	$224,903
AbbVie	55	$218,712
Astrazeneca UK Limited	4	$209,259
Janssen Research & Development, LLC	32	$203,586
Genmab U.S., Inc.	37	$147,558
Takeda Pharmaceuticals U.S.A., Inc.	25	$105,083
Beone Medicines Ltd.	4	$55,740
Daiichi Sankyo Inc.	21	$44,242
Genentech, Inc.	1	$37,000
Amgen	4	$36,707
Coherus Oncology, Inc.	4	$27,982
Beone Medicines USA, Inc.	1	$26,600
Genentech USA, Inc.	33	$871
Johnson & Johnson	26	$664
Lilly USA, LLC	19	$501
Bristol Myers Squibb	18	$497
Merck	19	$363
E.r. Squibb & Sons, L.L.C.	15	$300
Sanofi	5	$255
Gilead(2 entities)	7	$242
Incyte Corporation	8	$227
Amneal Pharmaceuticals LLC	8	$202
Tempus AI, Inc	4	$201
Astellas Pharma US Inc	9	$188
Jazz Pharmaceuticals Inc.	8	$180
Pharmacosmos Therapeutics Inc.	8	$165
Regeneron Healthcare Solutions, Inc.	7	$157
Seagen Inc.	5	$152
Mirati Therapeutics, Inc.	7	$139
Bayer	6	$125
GSK	4	$99
Exelixis Inc.	4	$80
Dendreon Pharmaceuticals LLC	2	$69
Cardinal Health 108 LLC	1	$68
Karyopharm Therapeutics Inc.	2	$63
AMAG Pharmaceuticals, Inc.	3	$60
Puma Biotechnology, Inc.	3	$59
Fresenius Kabi USA, LLC	2	$58
Pharmaessentia USA Corporation	2	$54
Accord Healthcare, Inc.	2	$53
Spectrum Pharmaceuticals Inc.	2	$52
Ipsen Biopharmaceuticals, Inc	2	$50
Stemline Therapeutics Inc.	2	$50
Array Biopharma Inc	2	$46
G1 Therapeutics, Inc.	2	$43
Biocon Biologics Inc	1	$42
Eisai Inc.	2	$36
Morphosys, US Inc.	2	$34
Syndax Pharmaceuticals, Inc.	1	$30
Boehringer Ingelheim	1	$30
Deciphera Pharmaceuticals Inc.	1	$28
Taiho Oncology, Inc.	1	$23
Angiodynamics, Inc.	1	$22
Agios Pharmaceuticals, Inc.	1	$22
Beigene USA, Inc.	1	$21
Epizyme, Inc.	1	$21

How this compares

$3,276,835 in reported general payments places this provider in the 95th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois →

Medicare billing

Part B allowed, 2024

$1,228,978

Medicare patients

181

Services billed

71,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Hinsdale

Richard SchilskyBurr Ridge$87.1M
Edwin PosadasBurr Ridge$70.9M
Oana DanciuChicago$23.2M
Shuo MaChicago$20.5M
Olwen HahnChicago$11.9M
Christine BestvinaChicago$11.3M
Russell SzmulewitzChicago$9.8M
Randy SweisChicago$9.4M
Hedy KindlerChicago$8.6M
Reem KarmaliChicago$7.7M

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →